结合甲胺A积累和氧化应激:一种针对质母细胞瘤的策略
Maria Vittoria Marvi1, Camilla Evangelisti1, Camilla Bruna Cerchier2
1Cellular Signalling Laboratory, Anatomy Centre, Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum-University of Bologna, Bologna, Italy.
European journal of cell biology
|April 30, 2025
概括
用SCH66336和Menadione向前拉胺A加工显示出质母细胞瘤治疗的前景. 这种方法减少了癌症干细胞的增殖和活力,为侵袭性脑瘤提供了潜在的新疗法.
科学领域:
- 神经瘤学神经瘤学
- 细胞生物学 细胞生物学
- 药物发现 药物发现
背景情况:
- 质母细胞瘤是一种具有有限治疗选择的侵袭性脑瘤.
- 目前的疗法提供了适度的生存益处,需要新的治疗策略.
- 质母细胞干细胞驱动瘤的攻击性和复发.
研究的目的:
- 调查一种针对质母细胞瘤中的前拉胺A处理的新疗法.
- 在质母细胞瘤细胞中使用SCH66336 (Lonafarnib) 抑制法内西尔转移酶的疗效.
- 评估SCH66336和Menadione对质母细胞干细胞的联合作用.
主要方法:
- 用SCH66336抑制法内西尔转移酶以促进先胺A的积累.
- 在质母细胞瘤细胞中使用Menadione诱导氧化应激.
- 评估细胞增殖,干细胞性标记物和患者衍生质母细胞干细胞的活力.
主要成果:
- SCH66336治疗促进了前胺A的积累,增加了质母细胞细胞对氧化应激的敏感性.
- 联合SCH66336-Menadione治疗降低了质母细胞瘤干细胞的增殖和活力.
- 联合治疗改变了质母细胞瘤干细胞中干性标记物的表达.
- 正常的人类星球细胞免于联合治疗的毒性影响.
结论:
- 抑制前胺A处理是一种潜在的策略,可以减少质母细胞瘤的攻击性.
- 这种方法提高了治疗结果,特别是对于耐治疗的质母细胞瘤干细胞种群.
- 干扰前胺A处理可以作为结质母细胞瘤治疗的补充策略.
关键词:
质母细胞瘤 (glioblastoma) 是一个质母细胞的干细胞拉明A/C A/C 是一个类型.拉米诺病变 拉米诺病变 拉米诺病变 拉米诺病变 拉米诺病变 拉米诺病变梅纳迪翁 (Menadione) 是一种可靠的药物.预胺A是一种先胺.这是SCH66336的价格.更多相关视频
相关概念视频
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...